Compare ACTG & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACTG | ASMB |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.9M | 440.0M |
| IPO Year | 1995 | 2010 |
| Metric | ACTG | ASMB |
|---|---|---|
| Price | $5.02 | $29.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 455.8K | 57.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 91.78 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $12,004,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $274.75 |
| P/E Ratio | $22.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.70 | $7.90 |
| 52 Week High | $5.21 | $39.71 |
| Indicator | ACTG | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 64.88 | 53.66 |
| Support Level | $4.77 | $26.71 |
| Resistance Level | $5.21 | $30.54 |
| Average True Range (ATR) | 0.16 | 1.47 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 56.18 | 73.59 |
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.